Retrospective Analysis of Concurrent Chemoradiation with the Combination of Bleomycin, Ifosfamide and Cisplatin (BIP) for Uterine Cervical Cancer

• Published in: The Tohoku Journal of Experimental Medicine Vol. 204; no. 4; pp. 309 - 315
• Main Authors: Aoki, Michiko, Akahira, Jun-ichi, Niikura, Hitoshi, Saito, Sumika, Abe, Yoriko, Aida, Takeshi, Sato, Naoko, Kitamura, Takako, Otsuki, Kenro, Katahira, Atsuko, Utsunomiya, Hiroki, Okamura, Chikako, Takano, Tadao, Ito, Kiyoshi, Okamura, Kunihiro, Yaegashi, Nobuo
• Format: Journal Article
• Language: English
• Published: Japan Tohoku University Medical Press 01.12.2004
• Subjects: Adult; Aged; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; BIP; Bleomycin - adverse effects; Bleomycin - therapeutic use; Carcinoma, Squamous Cell - drug therapy; Carcinoma, Squamous Cell - pathology; Carcinoma, Squamous Cell - radiotherapy; Carcinoma, Squamous Cell - therapy; cervical carcinoma; chemoradiation; Cisplatin - adverse effects; Cisplatin - therapeutic use; clinical trial; Combined Modality Therapy; Female; Humans; Ifosfamide - adverse effects; Ifosfamide - therapeutic use; Middle Aged; Radiation-Sensitizing Agents - therapeutic use; Retrospective Studies; Treatment Outcome; Uterine Cervical Neoplasms - drug therapy; Uterine Cervical Neoplasms - pathology; Uterine Cervical Neoplasms - radiotherapy; Uterine Cervical Neoplasms - therapy
• ISSN: 0040-8727; 1349-3329
• DOI: 10.1620/tjem.204.309

Combination chemotherapy consisting of bleomycin, ifosfamide, and ciplatin (BIP) is recognized as one of the most effective chemotherapies for uterine cervical cancer. However, there have been no reports that evaluate concurrent use of radiation with BIP. The objective of this study was to evaluate the toxicity and response of the combination of BIP concurrent with radiation in patients with squamous cell carcinoma of the uterine cervix. Eligibility criteria included patients who underwent radical hysterectomy (Type III hysterectomy) as a primary treatment and revealed lymph node metastases or deep myometrial invasion (stage IB and IIA) and patients who were previously untreated (stage IIB-IV). All of the patients had biopsy-proven squamous cell carcinoma of the uterine cervix. The patients received three courses of BIP chemoradiation, and the response and toxicity were evaluated. From January 2000 to December 2003, 30 patients met study eligibility criteria. All but three patients completed 3 courses of planned chemotherapy. The frequency of severe (grade 3 and 4) toxicity was as follows: anemia, 46.7%; neutrocytopenia, 73.3%; thrombocytopenia, 16.7%; and nausea and vomiting, 23.3%. Among 30 patients, 22 cases were evaluated for response. Complete response was achieved in 16 (72.7%) of patients, with a response rate of 90.9%. In conclusion, BIP chemoradiation seems to be superior to previously reported chemoradiation regimens, and has a potential as an optimal combination chemotherapy concurrent with radiation.